Pre-market trend | HENGRUI PHARMA (1276.HK) on May 13th surged with increased volume leading the pharmaceutical sector, is the bullish momentum about to start?

Yesterday's closing, HENGRUI PHARMA's Hong Kong stocks traded significantly actively, with a total transaction amount reaching HKD 464 million, which is considered high in the pharmaceutical sector. The stock price has recently been steadily climbing along the 5-day moving average, with the short-term moving average system showing a bullish arrangement. The MACD daily level has initially established a bullish signal, which usually indicates that the buying power is shifting from a wait-and-see approach to actively entering the market, and the momentum for confirming the short-term trend is beginning to strengthen. The volume is relatively ideal, and there are clear signs of a rebound in capital participation enthusiasm. On the news front, the global pharmaceutical industry has recently seen a continuous increase in attention, with Eli Lilly's oral weight loss drug research progress being widely discussed in the market. The GLP-1 sector continues to attract capital inflows, driving expectations for overall valuation recovery in the innovative drug sector. As a leading domestic innovative drug company, HENGRUI PHARMA has multiple research pipelines in critical clinical stages, and the market has high expectations for its overseas progress and commercialization of innovative drugs. Recently, capital inflows into the Hong Kong pharmaceutical sector have significantly accelerated, and the willingness of southbound funds to allocate to high-quality innovative drug targets has increased. The sector's linkage effect provides additional support for individual stock trends. From a technical perspective, HENGRUI PHARMA's current 5-day and 10-day moving averages are both rising, forming the first short-term support. If today's trading volume can maintain above HKD 400 million and stabilize above the short-term moving averages, the probability of challenging the previous range high points is increasing. However, after a continuous strengthening, intraday fluctuations are unavoidable, and if there is a pullback after a peak during the session, attention should be paid to changes in volume and the performance of HENGRUI PHARMA in the A-share market. The short-term trend reference is slightly bullish, with technical aspects and sector sentiment forming a phase resonance, but caution is needed for accumulated profit-taking after consecutive rebounds